The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development

Clinical development, not discovery, has become the defining bottleneck in biomedical innovation. Despite rising scientific investment, annual drug approvals have remained stubbornly flat for over a decade. The root cause is structural: fragmented systems, manual workflows, and reactive oversight that no longer scale to the demands of modern trial complexity.

This session charts the path from AI ambition to enterprise-scale deployment. We explore why agentic AI represents a fundamental shift in what's operationally possible in regulated clinical environments, what a structured activation journey looks like in practice, and what today's most capable clinical agents can already do.

Join us for this interactive session, which includes a live demo. Secure your spot today!

Key learnings:

• Why clinical operations are the critical bottleneck and how agentic AI, grounded in regulatory frameworks like 21 CFR Part 11 and ICH E6 R3, can expand operational capacity, reduce the systemic bottlenecks, and reshape the productivity curve of clinical development.
• What "activation to scale" actually means, including the implementation journey from pilot to production, and how sprint activation compresses the path to measurable, enterprise-scale agent deployment.
• How purpose-built clinical agents work in practice, where you’ll meet agents already primed for orchestration, such as Medable’s CRA, TMF, & PI Summary Agents, and more. See how they assist with risk detection, QTL monitoring, eCOA oversight, and compliance while acting as expert collaborators, not just tools.